Open AccessCandidemia in COVID‐19 treated with corticosteroids and tocilizumab
Author(s) -
Yamamoto Koichiro,
Nakamura Kaoru,
Hagiya Hideharu,
Otsuka Fumio
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4858
Subject(s) - medicine , tocilizumab , covid-19 , intensive care medicine , immunology , virology , disease , outbreak , infectious disease (medical specialty) , rheumatoid arthritis
COVID‐19 patients treated with anti‐inflammatory drugs are rarely complicated by candidemia. Since immunosuppressive therapy can blunt inflammatory reactions, clinicians should actively survey latent candidemia during severe COVID‐19 treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom